Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PON1 status.

Paraoxonase (PON1) has been termed an environmental response enzyme for its function in the detoxification of organophosphate pesticides, nerve agents and pharmaceuticals such as glucocorticoids and statins, as well as its cardioprotective role in breaking down oxidized LDL. PON1(192) genotype can be predicted with high accuracy from an examination of the two-dimensional plot of paraoxon and diazoxon hydrolysis rates [ 1]. Individuals for whom this functional genomic assay failed to predict PON1(192) genotype, or who had a low PON activity relative to others with the same genotype, were predicted to have genetic alterations that explained the inconsistency. Sequencing of the PON1 region of 23 Caucasian individuals detected a nonsense mutation changing amino acid 194 from a Trp to a stop codon (PON1(Trp194stop)). It was predicted that subjects who genotyped as PON1(192QR) but phenotyped as PON1(192QQ) or PON1(192RR) might carry the protein truncation mutation for which the defective product failed to be detected by the phenotyping assay. Screening of the five discordant subjects resulted in the detection of a single Caucasian carrying the stop codon, and determined its phasing on the PON1(192R) allele. Sequencing confirmed the change and revealed an additional subject with a likely deletion of the 5' end of the PON1 gene. Additional sequencing of 25 subjects with low PON1 activities identified two additional previously undescribed PON1 mutations, which may affect PON1 function: PON1(Pro90Leu) associated with the PON1(192Q) allele and PON1(Asp124missplice) associated with the PON1(192R) allele.

[1]  P. Durrington,et al.  Paraoxonase Status in Coronary Heart Disease: Are Activity and Concentration More Important Than Genotype? , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[2]  G. Jarvik,et al.  Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. , 2001, American journal of human genetics.

[3]  G. Jarvik,et al.  Polymorphisms in the human paraoxonase (PON1) promoter. , 2001, Pharmacogenetics.

[4]  G. Schellenberg,et al.  Paraoxonase (PON1) Phenotype Is a Better Predictor of Vascular Disease Than Is PON1192 or PON155 Genotype , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[5]  Y. Ikeda,et al.  A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. , 2000, Atherosclerosis.

[6]  A. Righetti,et al.  Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. , 2000, Circulation.

[7]  C. Furlong,et al.  Determination of paraoxonase (PON1) status requires more than genotyping. , 1999, Pharmacogenetics.

[8]  R. Walker,et al.  Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[9]  Jeetesh V. Patel,et al.  Serum paraoxonase after myocardial infarction. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[10]  Yasuhiro Watanabe,et al.  Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. , 1997, Biochemical and biophysical research communications.

[11]  S. Adkins,et al.  Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. , 1993, American journal of human genetics.

[12]  D. Adler,et al.  The molecular basis of the human serum paraoxonase activity polymorphism , 1993, Nature Genetics.

[13]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.